Investor Presentation

March 19, 2019

TherapeuticsMD[®]

For Her. For Life.

TherapeuticsMD.com

Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY[®], ANNOVERATM, BIJUVATM and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; the length, cost and uncertain results of future clinical trials; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock and the concentration of power in our stock ownership.

This non-promotional presentation is intended for investor audiences only.

Therapeutics MD[®]

New Product Launches Address Large Market Opportunities in Women's Health

	* Invexy* (estradiol vaginal inserts) 4 mcg • 10 mcg	Bijuva [™] 1mg/100 mg (estradiol and progesterone) capsules	ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)	
Key Value Proposition	Easy to use, lowest effective dose, designed to support patient adherence	First and only bio-identical FDA- approved combination product	First and only patient-controlled, procedure-free, long-acting, reversible birth control product	
Affected US Population	32 million women ^{1,2}	36 million women ⁴	43 million women ⁶	
US TAM Opportunity	>\$20B³	>\$25B ^{3,5}	\$5B ⁷	
Status	Approved May 29, 2018 Commercial Launch: August 2018	Approved October 28, 2018 Commercial Launch Expected: 2Q19 (April)	Approved August 10, 2018 Commercial Launch Expected: 2H19 (targeting 3Q)	

 The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.
Construit Conductor Statement of State Database and and literation of a second statement of the North American Menopause Society.

2) Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. Menopause. 2011;18(11):1160–1171.

3) Based on market pricing of current FDA-approved HT products.

Derived from U.S. Census data on women in the age group who normally experience symptoms.

5) Based on pre-WHI annual scripts of FDA-approved HT products.

6) Contraceptive Use in the United States, Guttmacher, July 2018. IQVIA Patient Tracker.

7) QuintilesIMS MIDAS, QuintilesIMS Analysis, Company filings. Long acting reversible contraceptive market includes: Nexplanon/Implanon, Mirena family, Paragard and Liletta. Net sales as reported in company filings.

Therapeutics MD°



Approved for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.



IMVEXXY is Clearly Differentiated from Other Treatment Options

Owning <u>clinical</u> attributes with the underpinning of a <u>highly effective patient experience</u>

Key Clinical Attributes:

1	New lowest approved dose				
2	Strong efficacy and safety data				
3	Improvement seen as early as 2 weeks (secondary endpoint)				
4	PK data where systemic hormone levels remain within normal postmenopausal range				
Key Physical Attributes:					
5	Ease of use and absence of applicator				
6					
	Ability to be used any time of day				
7	Ability to be used any time of day A mess-free way to administer				



Therapeutics MD[®] For Her. For Life.

∛Imvexxy.

Strong *****Invexxy[•] Launch

IMVEXXY (estradiol vaginal inserts) Launch Metrics				
Total paid scripts dispensed to patients ¹ (since launch through Feb. 28, 2019)	~109,600			
Total paid scripts (February 1-28, 2019)	~23,600			
Total patients (since launch through Feb. 28, 2019)	~37,600			
Total prescribers ² (since launch through Feb. 28, 2019)	~9,000			

Comparison of Average Weekly & Daily Script Volume (Average Weekly Volume: TRx for month / # days in month * 7 days)				
For 31 Days in For 28 Days in Jan. 2019 Feb. 2019				
Average weekly volume	~5,300	~5,900		
Average daily volume	~758	~842		

The company anticipates providing updates on a monthly basis


¹ Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. This includes a two week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.

Therapeutics MD°

For Her. For Life.

² Total Unique Prescribers that have sent a prescription to a pharmacy for at least 1 patient for IMVEXXY.

Successful Launch Execution



*Month 8 for IMVEXXY is February 2019

References:

1. Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program.

TherapeuticsMD[®] For Her. For Life.

- 2. Osphena and Intrarosa sourced is Symphony Health Integrated Dataverse.
- 3. Vagifem sourced from IQVIA National Prescriber Level Data.
- 4. All trademarks are the property of their respective owners.

Strong Patient Adherence & Compliance

through February 28, 2019

	IMVEXXY Patient Compliance ^{1,2}				
	Month Initial Prescription Filled	Average # Fills for those Patients	Maximum Allowable Fills Given the Month of Initial Fill		
	January 2019	1.9 Fills	2 Fills		
	December 2018	2.5 Fills	3 Fills		
	November 2018	3.2 Fills	4 Fills		
	October 2018	3.6 Fills	5 Fills		
	September 2018	4.3 Fills	6 Fills		
	August 2018	5.5 Fills	7 Fills		


Example of calculation: For patients who filled their initial prescription in November 2018, each of those patients averaged 3.2 fills from November 2018 through February 2019

Average fills for all patients through February 28, 2019 = 2.9³

Therapeutics MD[®] ¹Average number of fills per patient is the average number of fills per patient grouped by their initial month on therapy. ²Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. ³Average number of fills for all patients is calculated as Total Rx / Total Patients.

*** Invexxy** Commercial Payer Update

TRx Payer Breakdown of FDA-Approved VVA Products¹



Top 10 Plans Account for ~73% of all Commercial Pharmacy Lives

Plan	% of Lives ²	Status ³
CVS	15.5%	
ESI	15.4%	Adjudicating as of 10/1/18
United	7.6%	Adjudicating as of 3/1/19
Anthem	7.4%	Adjudicating as of Aug. 2018
Prime	6.6%	Adjudicating as of 1/1/19
OptumRx	6.1%	Adjudicating as of 1/1/19
Kaiser	4.7%	
Aetna	4%	
Cigna	4%	Adjudicating as of 12/15/18
EnvisionRx	1.8%	Adjudicating as of 1/1/19

Adjudication of claim by payer: IMVEXXY is on payer formulary as covered product and is being submitted to insurance company for payment by payer to pharmacy.

Therapeutics MD[®]

For Her. For Life.

¹IMS Data April 2018 ²Plan numbers as of January 2019 ³MMIT February 2019 and Account Insights

* Invexxy[®] Medicare Part D Payer Update

United and Kaiser Medicare Part D are Now Adjudicating (Paying)

Medicare Part D Update

- United Healthcare and Kaiser Medicare Part D are now adjudicating
- United Healthcare is the largest Medicare Part D payer
- Bids submitted for other Medicare Part D plans

Top 6 Plans Account for ~75% of all Medicare Part D Pharmacy Lives

Plan	% of Lives ¹	Status ²
United	21.1%	Adjudicating as of 2/1/19
Humana	18.9%	
CVS Caremark	14.7%	
Wellcare with Aetna lives	3.8%	
Express Scripts/ Cigna	3.5%	
Kaiser	3.7%	Adjudicating Maintenance Pack as of 10/1/18

¹Plan numbers as of January 2019 ² MMIT February 2019 and Account Insights

Therapeutics MD°

*** Invexxy**[®] Growth Levers in 2019









Lever 1: HCP Education and Patient Affordability

- ~9,000 targets have written as least 1 IMVEXXY prescription
- Patients pay no more than \$35 per prescription
- Sales force expanded to approximately 200 representatives

Lever 2: Payer Access

- Commercial contracts with majority of top payers signed
- Medicare Part D contracting underway

Lever 3: Market Expansion

- Maximize launch through BIO-IGNITE
- Expand medical education with the goal of 70 Speaker programs in 1Q19
- Avg. prescriber attendance 14 vs 2.3 industry avg.

Lever 4: Consumer

- DTC rollout in 2H19
- Launching when HCP awareness and education is established

Therapeutics MD°

Synergies Provide Potential to Expand the Market

BIJUVA is a Significant Sales Force Pull-Through Opportunity for IMVEXXY in 2019

- VMS and VVA are different symptoms of menopause¹ that are addressed with BIJUVA and IMVEXXY in one complementary product portfolio
- Menopausal women often experience both VVA and hot flashes together
 - Women that are being treated with hot flashes may experience VVA symptoms that need to be treated with a separate VVA prescription²
 - Systemic therapy for hot flashes may be ineffective for the treatment of VVA
 - BIJUVA can be leveraged for early awareness of VVA and IMVEXXY to make patients aware of IMVEXXY 10-15 years earlier before patients are exposed to competitive products
- Sales force to leverage this unique opportunity to expand IMVEXXY market





Bijuva[™] (estradiol and progesterone) capsules 1.0mg/100mg

The first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral softgel capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

Therapeutics MD[®]

Vasomotor Symptoms are the Most Common Symptoms Associated with Menopause¹



Vasomotor symptoms are extreme thermoregulatory responses characterized by episodes of profuse heat accompanied by sweating and flushing^{2,3}

- Also known as hot flashes or strong feelings of heat or sweating
- Occur predominantly around the head, neck, chest, and upper back



Vasomotor symptoms are experienced by the majority of women during the menopausal transition³

- As many as 74% of menopausal women¹
- Up to 88% of perimenopausal women¹




Moderate to severe vasomotor symptoms typically continue for 4 to 5 years following menopause and may last more than 10 years after final menstrual period in some women^{4,5}

References

1. Rapkin AJ. Am J Obstet Gynecol. 2007;196(2):97-106. 2. Deecher DC et al. Arch Womens Ment Health. 2007;10(6):247-257. 3. Thurston RC et al. Obstet Gynecol Clin North Am. 2011;38(3):489-501. 4. Freeman EW et al. Menopause. 2014;21(9):924-932. 5. Kleinman NL et al. JOEM. 2013;55(4):465-470.

TherapeuticsMD[®] For Her. For Life.

WHI Impact on FDA Approved Hormone Therapy



Symphony Health PHAST Data Excludes products for VVA category of products

Therapeutics MD°



BIJUVA Substitutable Market

FDA-App						
Off-Label Separate Bio-Identical E & P Pills	Combination Synthetic E+P ¹	Compounded Combination Bio-Identical E+P				
~3.9 million TRx (each) ¹	~2.5 million TRx ²	12 million – 18 million TRx ³				
~\$836M ⁴ TAM	~\$536⁴ TAM	~\$2.5B-\$3.8B ⁴ TAM				
2 copays	1 copay	Often 2 copays cash out of pocket				
Compliance risk	No compliance risk	Compliance risk				
Insurance coverage	Insurance coverage	Almost 100% out of pocket				

1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2018

2) Includes the following drugs: Activella[®], FemHRT[®], Angeliq[®], Generic 17b + Progestins, Prempro[®], Premphase[®], Duavee[®], Brisdelle[®]

3) Composite of Fisher, J. QuintilesIMS, White Paper: A Profile of the US Compounding Pharmacy Market, internal surveying of compounding pharmacies & NAMS publications 4) Based on WAC pricing of \$214.50



BIJUVA is indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause

Key Clinical Attributes


- First and only bio-identical combination of estradiol to reduce moderate to severe hot flashes combined with progesterone to help reduce the risk to the endometrium
- Demonstrated efficacy and safety data
 - Clinically meaningful improvements in quality of life and sleep disturbance data (secondary endpoints)
- Favorable lipid, coagulation and metabolic profiles
- Low incidence of bleeding and somnolence

Key Physical Attributes

- Once-a-day single oral softgel capsule only approved continuous combined progesterone product
- One prescription, one copay


Therapeutics MD°

No Clinically Significant Changes in Coagulation Parameters were Observed with BIJUVA



No Clinically Significant Changes in Lipid Parameters were Observed

In REPLENISH, lipid parameters were measured at baseline and Month 12



Improvement in Quality of Life Measures

Clinical Global Impression (CGI)

 Significantly more women rated their condition as very much or much improved with BIJUVA compared with placebo at Weeks 4 and 12

Menopause-Specific Quality of Life Questionnaire (MENQOL)

 Statistically significant improvements in total score were observed at Week 12, Month 6, and Month 12 compared with placebo

Medical Outcomes Study Sleep Scale (MOS-Sleep)


 Statistically significant improvements in total score were observed at Months 6 and 12 compared with placebo[†]

*P<0.001 vs placebo.

[†]Mean change from baseline at Month 12 was not significant.


Reference Data on file, TherapeuticsMD.

Bijuva



Therapeutics MD°

A Large Target Market for Bijuva




1) Symphony Health Solutions PHAST Data powered by IDV; 12 months as of December 31 2018

2) Based on WAC pricing of \$214.50

3) Composite of Fisher, J. QuintilesIMS, White Paper: A Profile of the US Compounding Pharmacy Market, internal surveying of compounding pharmacies & NAMS publications

Payer Breakdown of FDA-Approved VMS Products¹



¹ IMS Data 2018

Bijuva

Compared to IMVEXXY
Medicare Part D is a smaller
segment of the population
Expect 6 month commercial
payer block and similar payer
onboarding timeline to


IMVEXXY

Therapeutics MD°

For Her. For Life.


22

2019 TXMD Salesforce Expansion



Therapeutics MD°

Regulatory Environment Continues to Favor FDA-Approved Products



3) https://www.ascp.com/sites/default/files/Joint%20USP%20letter%202015%20FINAL.pdf


24

What is an Independent Community Compounding Pharmacy?

There are more than 23,000 independent community pharmacies across the United States

These pharmacies dispense approximately 40% of the nation's retail prescription drugs

- 72% of independent community pharmacies that compound prescriptions provide non- sterile compounding services only.
- The target audience is independent community pharmacies that compound
 20% or more of their total business.
- 3,000+ locations meet class of trade definition of which 700+ have highest BHRT volume



TherapeuticsMD[®] For Her. For Life.

Bio Ignite Progress and Results

Partnerships with Large Pharmacy Network and Individual Pharmacies

# of Pharmacies	Combination Bio-Identical E+P Scripts
>300 Pharmacies	~1,500,000 prescriptions annually
>400 Pharmacies with Prescription Data	>500,000 prescriptions annually
~100 Pharmacies (vetting process)	Currently evaluating
	>300 Pharmacies >400 Pharmacies with Prescription Data ~100 Pharmacies

*Formerly known as Premier Value Pharmacy Compounding Network. Each network pharmacy has the option to participate in Bio-Ignite and is not required to as a Artiria member.

Therapeutics MD°



Program Stats (6 Months since Pilot):

Live Accounts Dispensing IMVEXXY now or shortly in anticipation for BIJUVA: 29 (up 7 from Feb. 22, 2019)

States Reached: 31

• AK, AL, AR, AZ, CA, CO, CT, FL, GA, IA, ID, KS, LA, MA, MD, MI, MO, MS, NC, NJ, NV, NY, OH, OK, PA, RI, SC, TN, TX, VA, WA


Compounding Pharmacies in Vetting Process: 116

Unique CBHRT Prescribers Identified: 2,903 as of March 1, 2019



National High-Decile Compounding Pharmacies and TXMD Sales Team Overlap

- Yellow indicates field sales territory reach
- Red, Blue and Green indicate Compounding Pharmacy Targets
- Black Stars indicate TXMD pharmacy rep location



*This does not include the sales expansion territories

Therapeutics MD°

ANNOVERA[™]

(Segesterone Acetate/Ethinyl Estradiol Vaginal System)

Approved for use by females of reproductive potential to prevent pregnancy. (Limitation of use: Not adequately evaluated in females with a body mass index of >29 kg/m2).

TherapeuticsMD[®] For Her. For Life.

ANNOVERA - 1-Year Vaginal System

First and only patient-controlled, procedure-free, long-acting, reversible birth control

- ANNOVERA approved on August 10, 2018
 - 21/7 days cyclical dosing regimen for one year (13 cycles)
 - Segesterone acetate component of ANNOVERA was classified as a new chemical entity (NCE) with 5 years of regulatory exclusivity
- Developed by the Population Council developer of multi-billion dollar long acting contraceptive products
 - ParaGard[®] and Mirena[®] IUDs; Norplant[®] and Jadelle[®] implants; and Progering[®]

ANNOVERA Clinical & Physical Attributes

Clinical Attributes

- Highly effective in preventing pregnancy when used as directed (97.3%)
- Low daily release of ethinyl estradiol (13 mcg)
- Only product with new novel progestin segesterone acetate¹
 - No androgenic, estrogenic or glucocorticoid effects at contraceptive doses
- Favorable side effect profile including low rates of discontinuation related to irregular bleeding (1.7%)
- Safety profile generally consistent with other CHC products, including boxed warning

Physical Attributes

- "Vaginal System" the only product in a new class of contraception with potential for \$0 co-pay
- The vaginal system is composed of a "squishy" silicone elastomer
- Acceptable for women who haven't had a child (nulliparous) or are not in a monogamous relationship¹
- Cost and convenience (pharmacy and doc visits)
- Does not require refrigeration by HCP
- More pliable than NuvaRing

¹ Narender Kumar, Samuel S. Koide, Yun-Yen Tsong, and Kalyan Sundaram. 2000. *"Nestorone: a Progestin with a Unique Pharmacological Profile,"* Steroids 65: 629-636

For Her. For Life.

Therapeutics MD[®]

Segesterone Acetate/Ethinvl

Estradiol

Segesterone Acetate

Phase 3 Acceptability Study

Demonstrated 1-Year Contraceptive Vaginal System High User Satisfaction

Acceptability Data¹

- Phase 3 acceptability study (n=905 subjects)
- Overall satisfaction 89% related to ease of use, side effects, expulsions/feeling the product, and physical effect during sexual activity
- High rates of adherence (94.3%) and continuation (78%)


Ease of inserting (N=905)	Ease of removing (N=905)	Ease of remembering CVS insertion (N=905)	Ease of remembering CVS removal (N=905)	No side effects reported on questionnaire (N=905)
90.8%	88.2%	87.6%	85.2%	81.8%
(n=823)	(n=798)	(n=793)	(n=771)	(n=740)

¹Merkatz, Ruth B., Marlena Plagianos, Elena Hoskin, Michael Cooney, Paul C. Hewett, and Barbara S. Mensch. 2014. "Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: Development of a model; implications for introduction," *Contraception* 90(5): 514–521.

TherapeuticsMD[®] For Her. For Life.

Reversible Birth Control Market in the U.S.

2017 Women's Use of Contraception (Total 29 Million Women)




- OC's continue to lose market share to longer acting solutions such as IUDs, Implants and Rings
- IUDs and Implants are experiencing significant growth as the market shifts towards long-acting solutions

Source:

Centers for Disease Control and Preventions, NCHS, December 2018, No. 327 Data Brief 173, Current Contraceptive Status Among Women Aged 15-44: United States, 2011-2013

Therapeutics MD°

ANNOVERA – Addressing an Unmet Need Target Market Segments



Therapeutics MD°

ANNOVERA Key Attributes

	Oral Contraceptives	Vaginal Ring NuvaRing®	Contraceptive Injection	Vaginal System ANNOVERA™	IUDs
Duration of Action	Daily pill intake	1 month (21/ 7 regimen)	3 months	1 year (21/7 regimen)	3-10 years
Patient Control	Stop at any time	Removable at any time	Stop at any time, but residual effects for 3 months	Removable at any time	Procedure required
Nulliparous Women	Yes	Yes	Yes	Yes	Not universally acceptable
Product Administration	Oral intake	Patient administered Semi-rigid ring	Physician in-office injection every 3 months	Patient administered pliable vaginal system	Physician in-office procedure for insertion and removal
Patient Convenience	Daily pill presents compliance/ adherence risks; potential increase in unplanned pregnancies	Monthly pharmacy visit	Physician in-office injection, prescriber stocking required	1 doctor's visit, 1 pharmacy visit per year	Physician in-office procedure prescriber stocking required
Healthcare Provider Convenience	Filled at pharmacy	Filled at pharmacy; Refrigeration required prior to being dispensed	Prescriber required to hold inventory	Filled at pharmacy; No refrigeration; No inventory or capital outlay	Prescriber required to hold inventory
Yearly WAC	Lo Loestrin® Fe: \$1,829.36	NuvaRing® \$2,114.19	Depo-Provera [®] \$799.12	\$1,800-\$2,000	Liletta® \$749.40 + \$425.25 for insertion/removal Plus office visits and screenings

All trademarks are the property of their respective owners.

For Her. For Life.

Key Planned Levers for Growth





ANNOVERA[™]

(segesterone acetate and ethinyl estradiol vaginal system)

- IQ 2019 50 additional sales reps added
- 1Q 2019 Maximize IMVEXXY launch through BIO-IGNITE
- 1Q 2019 Speaker programs throughout the U.S. highlighting the clinical and physical attributes of IMVEXXY
- IQ 2019 through 3Q 2019 Expand IMVEXXY Part D coverage
- 2H 2019 Begin direct-to-consumer marketing for IMVEXXY

- 2Q 2019 (April) U.S. commercial launch of BIJUVA and draw second \$75 million debt tranche with
- MidCap Financial Trust
- 4Q 2019 "new to market" 6-month payer block to end
- 4Q 2019 Maximize BIJUVA launch through BIO-IGNITE
- BIJUVA WAC price set at \$214.50
 - Priced at parity to legacy hot flash products
 - Aligned with TXMD responsible pricing strategy
 - Strategic payer strategy

- 2H (targeting 3Q) 2019 U.S. commercial launch of ANNOVERA
- IQ 2020 "new to market" 6-month payer block to end
- ANNOVERA WAC price expected to be \$1,800-\$2,000
 - Priced at a discount to NuvaRing
 - Aligned with TXMD responsible pricing strategy
 - Strategic payer strategy
 - Potential 19th category of contraception
- 2H 2019 Currently evaluating debt funding for launch of ANNOVERA

Summer 2019 - Company to hold Analyst Day to highlight portfolio and launch strategies

Therapeutics MD°

Opportunities to Strengthen our Position Once All 3 Products are Launched and Covered

- 1Q 2020 All 3 products are expected to be covered by payers
- Based on volume generated by 3 products concentrated in women's health care, TXMD can optimize distribution costs, relationships and partnerships
- Strong women's health care platform created to negotiate and refine payer rebates and coverage
- Maximize copay assistance program through patient targeting and compliance
- Achieve critical mass and optimal voice in provider offices by offering 3 new products that cover many of the day-to-day needs of OBGYN's
- Begin lifetime of patient strategy to build brand loyalty and awareness



TherapeuticsMD, A Premier Women's Health Company





Therapeutics MD°